Demyelinating Diseases
This microlearning reviews myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a focus on the 2023 International MOGAD Panel diagnostic criteria.
Collaborating with Mayo Clinic Laboratories, UNC Health streamlined neuroimmunology test ordering — eliminating outmoded testing and elevating diagnostic accuracy.
Recording coming soon. Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.
Learn more about the risks of false positives with AQP4 ELISA methodology in CNS demyelinating disease testing.
Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.
Mayo Clinic Laboratories’ MS testing cascade, which starts with kappa free light chain (KFLC) testing and reflexes to oligoclonal banding when indicated, is supported by the revised 2024 McDonald Criteria. This approach delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.
Mayo Clinic Laboratories invites you to explore our latest microlearning on neuromyelitis optica spectrum disorder (NMOSD). In this concise educational module, Sean Pittock, M.D., explains the critical role of AQP4-IgG testing in the early diagnosis and treatment of NMOSD.
By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.
Tying together the expertise and curiosity of Mayo Clinic autoimmune neurology researchers with eager patients who have rare disease and are looking for answers, the innovative collaboration benefits both patients affected by MOGAD and scientists on the front lines of discovery.
Joe Mondloch and his wife Sue have existed in a grey area of uncertainty due to the unpredictable autoimmune neurological illness Joe has lived with for the last seven years. Rare, incurable, and debilitating, the newly classified disorder can be hard to manage. But thanks to information and direction provided by a rare disease advocacy group, the Mondlochs sought care at Mayo Clinic and received much more than answers.
Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional oligoclonal banding, enabling definitive answers for the challenging diagnosis.
Lying in an ICU bed as sick as he could get, Jon Bratsch thought he was past the point of no return. But when a Mayo Clinic Laboratories’ test revealed the source of his dire symptoms, everything changed. Today, Jon’s back to the life and family he loves.